Tilray Brands (TLRY) Profit After Tax Growth (1y) (2018 - 2026)
Tilray Brands (TLRY) Profit After Tax Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 67.73% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -388.33% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1,682.88% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | Tilray Brands | 454.65 Mn | 394.45 Mn | 54.95 Mn | 96.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 96.21% |
| Nov 30, 2025 | 58.57% |
| Aug 31, 2025 | 104.35% |
| May 31, 2025 | -10,206.21% |
| Feb 28, 2025 | -651.97% |
| Nov 30, 2024 | -129.97% |
| Aug 31, 2024 | 42.09% |
| May 31, 2024 | 89.48% |
| Feb 29, 2024 | -17,597.17% |
| Nov 30, 2023 | 60.55% |
| Aug 31, 2023 | 60.25% |
| May 31, 2023 | 82.71% |
| Feb 28, 2023 | -98.61% |
| Nov 30, 2022 | -142.27% |
| Aug 31, 2022 | 2.63% |
| May 31, 2022 | -1,527.64% |
| Feb 28, 2022 | 115.79% |
| Nov 30, 2021 | 52.45% |
| Aug 31, 2021 | -568.13% |
| May 31, 2021 | 154.19% |